Real-world evidence supports efficacy of and shows lower toxicity in Kymriah CAR-T Therapy
- Two studies looking at patients with diffuse large B cell lymphoma (DLBCL) and acute lymphoblastic leukaemia (ALL) were presented at ASH, looking at Novartis’ CAR-T therapy, Kymriah (tisagenlecleucel).
- Both studies supported the pre-regulatory approval clinical trials data, with Kymriah achieving high response rates, and in fact saw fewer serious side effects, such as neurotoxicity.
- This data bolsters Kymriah’s clinical profile as it challenges Gilead’s CAR-T, Yescarta (axicabtagene ciloleucel), also approved for DLBCL, for market share.
Click here to read the source article
SVMPharma is an innovative strategic consultancy, specialising in Real World Evidence (RWE) for the pharmaceutical industry. SVMPharma generates RWE within UK and Europe through bespoke online Real World Treatment Evaluators, leading to successful health technology appraisal (HTA) submissions. Clinical trial programmes do not reflect real-world clinical practice and outcomes, RWE supplements and enhances clinical datasets. SVMPharma’s specialist teams focus on delivering the outcomes that matter to your brand.